Komori
Tohoku Chemical (7446) · TargetAchieved

FY2021/9 targets: consolidated net sales of ¥31.8 billion and consolidated ordinary profit of ¥425 million

First written in FY2020. 2 of 4 entries say "Advanced", first in FY2021-Q2. Latest entry: FY2021.

4entries
2years
0from disclosures
Share on X
How it moved
ProgressHeldSoftenedWorseFirst statedFY2020AdvancedFY2021-Q2 – FY20212020: 12021: 32021
Same theme, other companies
Consolidated performance targets for the fiscal year ending September 2021A theme 1 companies write about · 0 as a headwind · 1 as a tailwind

No other company in this theme has enough history to compare yet.

Full recordFilings, disclosures and news, newest first
  1. FY2021AchievedAnnual report

    「As a result, compared with the previous consolidated fiscal year, net sales increased by ¥5,180 million, or 16.7%, to ¥36,221 million; operating income increased by ¥351 million, or 97.5%, to ¥713 million; ordinary income increased by ¥348 million, or 85.0%, to ¥758 million; and net income attributable to owners of the parent increased by ¥138 million, or 36.6%, to ¥516 million.」

    Against the FY2021/9 targets of consolidated net sales of ¥31.8 billion and consolidated ordinary profit of ¥425 million, actual net sales were ¥36.221 billion and ordinary profit was ¥758 million, exceeding both targets.
  2. FY2021-Q3AdvancedAnnual report

    「As a result, compared with the same quarter of the previous year, net sales increased significantly by ¥4,464 million, or 19.6%, to ¥27,204 million; operating income increased significantly by ¥365 million, or 176.4%, to ¥571 million; ordinary income increased significantly by ¥357 million, or 142.6%, to ¥608 million; and net income attributable to owners of the parent increased significantly by ¥143 million, or 50.5%, to ¥427 million.」

    Against the FY2021/9 consolidated ordinary profit target of ¥425 million, ordinary profit for the cumulative third quarter was ¥608 million, exceeding the full-year target. Net sales were ¥27.204 billion, indicating progress toward the full-year target of ¥31.8 billion.
  3. FY2021-Q2AdvancedAnnual report

    「As a result, compared with the same quarter of the previous year, net sales increased significantly by ¥2,969 million, or 19.4%, to ¥18,289 million; operating income increased by ¥306 million, or 213.9%, to ¥449 million; ordinary income increased by ¥301 million, or 182.5%, to ¥466 million; and net income attributable to owners of the parent increased by ¥223 million, or 221.2%, to ¥323 million.」

    Against the FY2021/9 targets, ordinary profit for the cumulative second quarter was ¥466 million, exceeding the full-year target of ¥425 million. Net sales were ¥18.289 billion, progressing toward the full-year target of ¥31.8 billion.
  4. FY2020First statedAnnual report

    「The company’s management policy is to meet shareholders’ expectations and achieve further profit growth, and it has established the following management targets for FY2021/9. Target achievement period: FY2021/9; consolidated net sales: ¥31.8 billion; consolidated ordinary profit: ¥425 million.」

    The company has set consolidated net sales of ¥31.8 billion and consolidated ordinary profit of ¥425 million as management targets for FY2021/9.
Moved together

"Improving Performance Through Revenue and Profit Growth" moved the same way as this thread, in the same document, in 3 of its 4 moves.

3333★1234
  1. ★This thread
  2. 1Improving Performance Through Revenue and Profit Growth3×
  3. 2Recovery in demand related to electronic components and generic pharmaceuticals3×
  4. 3Expanding demand, new adoption and margin improvement for clinical laboratory reagents3×
  5. 4Increase in Total Assets, Liabilities and Net Assets3×

★ is this thread; numbers match the list above. The number on a line is how many documents both moved the same way in; lines between the other threads count the documents they moved together in too. Threads that move together often sit closer.

When this could move next
Tohoku Chemical's next results are scheduled for 2026-11-13. Read the earnings preview
News
No news is linked to this thread yet. When an article touches it, it will appear here by date.